Bronislaw Pytowski

9.1k total citations · 2 hit papers
61 papers, 6.5k citations indexed

About

Bronislaw Pytowski is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Bronislaw Pytowski has authored 61 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 37 papers in Molecular Biology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Bronislaw Pytowski's work include Angiogenesis and VEGF in Cancer (28 papers), Lymphatic System and Diseases (27 papers) and Sympathectomy and Hyperhidrosis Treatments (10 papers). Bronislaw Pytowski is often cited by papers focused on Angiogenesis and VEGF in Cancer (28 papers), Lymphatic System and Diseases (27 papers) and Sympathectomy and Hyperhidrosis Treatments (10 papers). Bronislaw Pytowski collaborates with scholars based in United States, Finland and Switzerland. Bronislaw Pytowski's co-authors include Daniel J. Hicklin, Kari Alitalo, Larry Witte, Yan Wu, Peter Böhlen, Kris Persaud, Zhenping Zhu, Seppo Ylä‐Herttuala, Luc de Witte and Marc G. Achen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Bronislaw Pytowski

61 papers receiving 6.3k citations

Hit Papers

Antivascular endothelial growth factor receptor (fetal li... 1999 2026 2008 2017 1999 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    1999 557 citations Bronislaw Pytowski, Luc de Witte et al. profile →
  2. Engraftment and Reconstitution of Hematopoiesis Is Dependent on VEGFR2-Mediated Regeneration of Sinusoidal Endothelial Cells
    2009 467 citations Larry Witte, Zhenping Zhu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bronislaw Pytowski United States 37 3.6k 3.5k 1.1k 923 790 61 6.5k
Mihaela Skobe United States 36 4.5k 1.3× 3.8k 1.1× 1.2k 1.1× 911 1.0× 901 1.1× 44 7.0k
Arja Kaipainen United States 40 4.8k 1.3× 6.7k 1.9× 1.6k 1.4× 971 1.1× 623 0.8× 57 10.0k
Vladimir Joukov Finland 27 4.2k 1.2× 5.8k 1.7× 984 0.9× 728 0.8× 463 0.6× 34 7.9k
Terhi Kärpänen Finland 32 4.5k 1.3× 4.0k 1.2× 1.3k 1.2× 1.1k 1.2× 691 0.9× 39 6.8k
Katherine N. Weilbaecher United States 46 3.2k 0.9× 2.5k 0.7× 375 0.3× 235 0.3× 1.3k 1.7× 124 6.1k
Andrew J. Connolly United States 42 1.5k 0.4× 3.0k 0.9× 1.6k 1.4× 487 0.5× 1.9k 2.4× 88 8.0k
Remko Prevo United Kingdom 25 4.1k 1.1× 3.7k 1.1× 1.0k 0.9× 676 0.7× 489 0.6× 34 5.8k
Berthold Streubel Austria 45 1.9k 0.5× 1.7k 0.5× 918 0.8× 457 0.5× 945 1.2× 149 6.5k
Tuomas Tammela Finland 40 5.7k 1.6× 5.2k 1.5× 2.1k 1.9× 1.4k 1.5× 1.0k 1.3× 64 9.9k
Petri Salvén Finland 29 2.4k 0.7× 3.4k 1.0× 528 0.5× 329 0.4× 501 0.6× 50 5.1k

Countries citing papers authored by Bronislaw Pytowski

Since Specialization
Citations

This map shows the geographic impact of Bronislaw Pytowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bronislaw Pytowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bronislaw Pytowski more than expected).

Fields of papers citing papers by Bronislaw Pytowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bronislaw Pytowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bronislaw Pytowski. The network helps show where Bronislaw Pytowski may publish in the future.

Co-authorship network of co-authors of Bronislaw Pytowski

This figure shows the co-authorship network connecting the top 25 collaborators of Bronislaw Pytowski. A scholar is included among the top collaborators of Bronislaw Pytowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bronislaw Pytowski. Bronislaw Pytowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Uhlik, Mark, Seema Iyer, Luka Ausec, et al.. (2023). Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers. Frontiers in Oncology. 13. 1158345–1158345. 3 indexed citations
2.
Saif, Muhammad Wasif, James A. Knost, E. Gabriela Chiorean, et al.. (2016). Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 78(4). 815–824. 56 indexed citations
3.
Falcón, Beverly L., Sudhakar Chintharlapalli, Mark Uhlik, & Bronislaw Pytowski. (2016). Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacology & Therapeutics. 164. 204–225. 112 indexed citations
4.
Quagliata, Luca, Natascha Cremers, Bronislaw Pytowski, et al.. (2013). Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model. Clinical & Experimental Metastasis. 31(3). 351–365. 15 indexed citations
5.
Benedito, Rui, Susana Rocha, Freddy Radtke, et al.. (2012). Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling. Nature. 484(7392). 110–114. 286 indexed citations
6.
Schwartz, Jonathan D., Eric K. Rowinsky, Hagop Youssoufian, Bronislaw Pytowski, & Yan Wu. (2010). Vascular endothelial growth factor receptor‐1 in human cancer. Cancer. 116(S4). 1027–1032. 69 indexed citations
7.
Burton, Jeremy B., Saul J. Priceman, James L. Sung, et al.. (2008). Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis. Cancer Research. 68(19). 7828–7837. 131 indexed citations
8.
Xue, Yuan, Piotr Religa, Renhai Cao, et al.. (2008). Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proceedings of the National Academy of Sciences. 105(47). 18513–18518. 57 indexed citations
9.
Laakkonen, Pirjo, Marika Waltari, Tanja Holopainen, et al.. (2007). Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth. Cancer Research. 67(2). 593–599. 184 indexed citations
10.
Kärpänen, Terhi, Maria Wirzenius, Taija Mäkinen, et al.. (2006). Lymphangiogenic Growth Factor Responsiveness Is Modulated by Postnatal Lymphatic Vessel Maturation. American Journal Of Pathology. 169(2). 708–718. 109 indexed citations
11.
Holash, Jocelyn, Gavin Thurston, John S. Rudge, et al.. (2006). Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer and Metastasis Reviews. 25(2). 243–252. 16 indexed citations
12.
Bałuk, Peter, Tuomas Tammela, Natalya Lyubynska, et al.. (2005). Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation. 115(2). 247–257. 470 indexed citations
13.
Cursiefen, Claus, Sakae Ikeda, Patsy M. Nishina, et al.. (2005). Spontaneous Corneal Hem- and Lymphangiogenesis in Mice with Destrin-Mutation Depend on VEGFR3 Signaling. American Journal Of Pathology. 166(5). 1367–1377. 48 indexed citations
14.
Chen, Lu, Pedram Hamrah, Claus Cursiefen, et al.. (2004). Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nature Medicine. 10(8). 813–815. 184 indexed citations
15.
Lü, Dan, Paul Kussie, Bronislaw Pytowski, et al.. (2000). Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies. Journal of Biological Chemistry. 275(19). 14321–14330. 59 indexed citations
16.
Witte, Larry, Daniel J. Hicklin, Zhenping Zhu, et al.. (1998). Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer and Metastasis Reviews. 17(2). 155–161. 262 indexed citations
17.
18.
Rockwell, Patricia, et al.. (1995). Isolation and Characterization of a Monoclonal Antibody Binding to the Extracellular Domain of the flk-2 Tyrosine Kinase Receptor. Hybridoma. 14(5). 453–459. 2 indexed citations
19.
Johnson, Linda S., Kenneth W. Dunn, Bronislaw Pytowski, & Timothy E. McGraw. (1993). Endosome acidification and receptor trafficking: bafilomycin A1 slows receptor externalization by a mechanism involving the receptor's internalization motif.. Molecular Biology of the Cell. 4(12). 1251–1266. 184 indexed citations
20.
Pytowski, Bronislaw, Thomas G. Easton, Jay E. Valinsky, et al.. (1988). A monoclonal antibody to a human neutrophil-specific plasma membrane antigen. Effect of the antibody on the C3bi-mediated adherence by neutrophils and expression of the antigen during myelopoiesis.. The Journal of Experimental Medicine. 167(2). 421–439. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mihaela Skobe Breakdown of academic impact, for papers by Arja Kaipainen Breakdown of academic impact, for papers by Vladimir Joukov Breakdown of academic impact, for papers by Terhi Kärpänen Breakdown of academic impact, for papers by Katherine N. Weilbaecher Breakdown of academic impact, for papers by Andrew J. Connolly Breakdown of academic impact, for papers by Remko Prevo Breakdown of academic impact, for papers by Berthold Streubel Breakdown of academic impact, for papers by Tuomas Tammela Breakdown of academic impact, for papers by Petri Salvén
Rankless by CCL
2026